Cited In for PMID: 25209969

Year	Number of Results
2014	1
2015	9
2016	5
2017	14
2018	9
2019	11
2020	6
2021	8
2022	7
2023	3
2024	0

1

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.

Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, Alvarez RD, Conner MG, Schneider D, Chen D, Landen CN. Dobbin ZC, et al. Oncotarget. 2014 Sep 30;5(18):8750-64. doi: 10.18632/oncotarget.2373. Oncotarget. 2014. PMID: 25209969 Free PMC article.

2

Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.

Oda Y, Niimi K, Yoshida K, Tamauchi S, Yokoi A, Yasui Y, Nishiko Y, Shibata M, Shimizu Y, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K, Yamamoto E, Kajiyama H. Oda Y, et al. BMC Cancer. 2023 Nov 13;23(1):1103. doi: 10.1186/s12885-023-11626-3. BMC Cancer. 2023. PMID: 37957624 Free PMC article.

3

Antitumor effect of toosendanin on oral squamous cell carcinoma via suppression of p-STAT3.

Wu Y, Chen L, Feng C, Wang T, He S, Zheng D, Lin L. Wu Y, et al. BMC Oral Health. 2023 Nov 9;23(1):846. doi: 10.1186/s12903-023-03602-x. BMC Oral Health. 2023. PMID: 37946196 Free PMC article.

4

Synergistic combination therapy delivered via layer-by-layer nanoparticles induces solid tumor regression of ovarian cancer.

Kong S, Moharil P, Handly-Santana A, Boehnke N, Panayiotou R, Gomerdinger V, Covarrubias G, Pires IS, Zervantonakis I, Brugge J, Hammond PT. Kong S, et al. Bioeng Transl Med. 2022 Nov 8;8(2):e10429. doi: 10.1002/btm2.10429. eCollection 2023 Mar. Bioeng Transl Med. 2022. PMID: 36925689 Free PMC article.

5

Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic.

Long Y, Xie B, Shen HC, Wen D. Long Y, et al. Cells. 2022 Nov 30;11(23):3868. doi: 10.3390/cells11233868. Cells. 2022. PMID: 36497126 Free PMC article. Review.

6

Harnessing preclinical models for the interrogation of ovarian cancer.

Qin T, Fan J, Lu F, Zhang L, Liu C, Xiong Q, Zhao Y, Chen G, Sun C. Qin T, et al. J Exp Clin Cancer Res. 2022 Sep 16;41(1):277. doi: 10.1186/s13046-022-02486-z. J Exp Clin Cancer Res. 2022. PMID: 36114548 Free PMC article. Review.

7

The organoid: A research model for ovarian cancer.

Chang YH, Wu KC, Harnod T, Ding DC. Chang YH, et al. Tzu Chi Med J. 2021 Jul 9;34(3):255-260. doi: 10.4103/tcmj.tcmj_63_21. eCollection 2022 Jul-Sep. Tzu Chi Med J. 2021. PMID: 35912056 Free PMC article. Review.

8

Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application.

Ciucci A, Buttarelli M, Fagotti A, Scambia G, Gallo D. Ciucci A, et al. Cell Mol Life Sci. 2022 Jun 16;79(7):364. doi: 10.1007/s00018-022-04395-y. Cell Mol Life Sci. 2022. PMID: 35705879 Free PMC article. Review.

9

A role for microfluidic systems in precision medicine.

Ayuso JM, Virumbrales-Muñoz M, Lang JM, Beebe DJ. Ayuso JM, et al. Nat Commun. 2022 Jun 2;13(1):3086. doi: 10.1038/s41467-022-30384-7. Nat Commun. 2022. PMID: 35654785 Free PMC article. Review.

10

Resistance to anti-tubulin agents: From vinca alkaloids to epothilones.

Krause W. Krause W. Cancer Drug Resist. 2019 Mar 19;2(1):82-106. doi: 10.20517/cdr.2019.06. eCollection 2019. Cancer Drug Resist. 2019. PMID: 35582143 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

68 results

Results by year